Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders.

Genetic testing and molecular biomarkers - 1 Jan 2000

Ayad Mona Wagdy, Nafea Dalia

Abstract excerpt

Janus Kinase 2 (JAK2) is a member of a family of four Janus Kinases, 2, and 3 and tyrosine kinase 2. Mutated JAK2 (V617F) has the ability to activate downstream signal transducer and activator of transcription (STAT)-mediated transcription in the absence of the ligand erythropoietin. The autoinhi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Janus Kinase 2

Share to Mutation

Share to Myeloproliferative Disorders

Source

Identifiers

PMID: 21034166
DOI: 10.1089/gtmb.2010.0093

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21034166-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders.PMID 21034166Read ↗

Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.Semantic proximity Read ↗

JAK2 and Beyond: Mutational Study of JAK2V617 in Myeloproliferative Disorders and Haematological Malignancies in Kashmiri population.Semantic proximity Read ↗

Screening of V617F mutation in JAK2 gene with acute myeloid leukemia in the Saudi population.Semantic proximity Read ↗

Prevalence of JAK 2 v617 Mutations in Malignant and Non-Malignant Tumors in the Eastern Province of the Kingdom of Saudi Arabia.Semantic proximity Read ↗

JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?Semantic proximity Read ↗

Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders.Semantic proximity Read ↗

Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.Semantic proximity Read ↗

Laboratory detection of JAK2V617F in human myeloproliferative neoplasms.Semantic proximity Read ↗

Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.Semantic proximity Read ↗

JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.Semantic proximity Read ↗

Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis.Semantic proximity Read ↗

[Progress of study on JAK2V617F mutation in myeloproliferative neoplasm].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.